Edit

PolyProx Therapeutics

http://www.polyprox.com/
Last activity: 02.03.2020
Active
Categories: BioTechDrugGrowthLifePropertyResearchUniversity
PolyProx Therapeutics is a spin out of the Department of Pharmacology at the University of Cambridge, and is based on over a decade of research and intellectual property from Founder, Professor Laura Itzhaki’s laboratory. Professor Itzhaki is joined at PolyProx Therapeutics by serial Cambridge biotech entrepreneurs Kevin Moulder as Chief Operating Officer and Andrew Sandham as Executive Chairman. PolyProx Therapeutics will develop a new class of drugs, called Polyproxin™ molecules, that are able to selectively target tumour cells and trigger the natural degradation machinery contained within the cell to arrest tumour growth.
Mentions
8
Total raised: $5.71M
Email

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
02.03.2020Seed$1.28M-
30.04.2019Seed$4.43M-

Mentions in press and media 8

DateTitleDescription
02.03.2020PolyProx raises an additional £1 million seed financing from new investor LifeArcPolyProx Therapeutics raises an additional £1 million seed financing from new investor, LifeArc, to validate polyproxin® drug leads in oncology Cambridge, UK: PolyProx Therapeutics, a biotechnology company focused on the discovery and devel...
02.03.2020PolyProx Therapeutics Raises Additional £1M in Seed FinancingPolyProx Therapeutics, a Cambridge, England, UK-based biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, raised an additional £1m in seed funding. New backer LifeArc made ...
02.03.2020PolyProx Therapeutics raises an additional £1m seed financing to validate polyproxin® drug leads in oncologyPolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, Lif...
02.03.2020PolyProx Therapeutics raises an additional £1m seed financing to validate polyproxin® drug leads in oncologyPolyProx Therapeutics raises an additional £1m seed financing to validate polyproxin® drug leads in oncology 02-03-2020 PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for ...
30.04.2019PolyProx Therapeutics raises £3.4m seed financing to validate novel class of cancer drugsPolyProx Therapeutics raises £3.4m seed financing to validate novel class of cancer drugs 30-04-2019 PolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment o...
30.04.2019CIC co-leads £3.4 million seed financing for PolyProx TherapeuticsFunding will support research operations to validate a novel class of drugs to treat cancer Cambridge Innovation Capital plc (CIC), the venture capital investor focused on technology and life science businesses in the Cambridge ecosystem, h...
30.04.2019PolyProx Therapeutics Raises £3.4m in Seed FinancingPolyProx Therapeutics, a Cambridge, UK-based biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, raised £3.4m in seed funding. The round was co-led by Cambridge Innovation ...
30.04.2019PolyProx Therapeutics raises £3.4m seed financing to validate novel class of cancer drugsPolyProx Therapeutics, a new biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announced that it has raised £3.4m of seed capital. A spin out of the Department of P...

Reviews 0

Sign up to leave a review

Sign up Log In